Recent developments in antifungal agents

International Journal of Pharmacy and Pharmaceutical Sciences

Volumn 4, Issue SUPPL. 4, 2012, Pages 4-10

  Talaviya, Smita ^a   Majmudar, Falguni ^b  

^a Shri AK Raval Charitable Trust   (India)

^b SMT NHL MUNICIPAL MEDICAL COLLEGE   (India)

Author keywords

Antifungal agents; Azoles; Echinocandins; Newer approaches

Indexed keywords

ALBACONAZOLE; AMINOCANDIN; AMPHOTERICIN B; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; ANIDULAFUNGIN; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CASPOFUNGIN; CLOTRIMAZOLE; CORTICOSTEROID; FLUCONAZOLE; GAMMA1B INTERFERON; HEAT SHOCK PROTEIN 90 ANTIBODY; ISAVUCONAZOLE; ISAVUCONAZONIUM; ITRACONAZOLE; KETOCONAZOLE; MICAFUNGIN; MICONAZOLE; MONOCLONAL ANTIBODY; NIKKOMYCIN; NYSTATIN; POSACONAZOLE; RAVUCONAZOLE; SORDARIN DERIVATIVE; UNCLASSIFIED DRUG; VORICONAZOLE;

ANTIFUNGAL ACTIVITY; ANTIMICROBIAL THERAPY; BLASTOMYCOSIS; CANDIDEMIA; CANDIDIASIS; CHEMOPROPHYLAXIS; COCCIDIOIDOMYCOSIS; CORTICOSTEROID THERAPY; DERMATOPHYTOSIS; DRUG ABSORPTION; DRUG EFFICACY; DRUG INDICATION; FUNGAL ENDOCARDITIS; HISTOPLASMOSIS; HUMAN; INFECTION RISK; INVASIVE ASPERGILLOSIS; INVASIVE CANDIDIASIS; MINIMUM INHIBITORY CONCENTRATION; MYCOSIS; NONHUMAN; REVIEW; SOUTH AMERICAN BLASTOMYCOSIS; SPOROTRICHOSIS; THRUSH; VAGINA CANDIDIASIS;

EID: 84866334140     PISSN: None     EISSN: 09751491     Source Type: Journal    
DOI: None     Document Type: Review

References (120)

1. Ellis M. Invasive fungal infections: evolving challenges for diagnosis and therapeutics. Mol Immunol. 2002;38:947-57.
2. Enoch DA, Ludlam HA, Brown NM. Invasive fungal infections: a review of epidemiology and management options. J Med Microbiol. 2006;55:809-818.
3. Edmond MB, Wallace SE, McClish DK, Pfaller MA, Jones RN, Wenzel RP. Nosocomial bloodstream infections in United States hospitals: a three-year analysis. Clin Infect Dis. 1999;29:239-44.
4. Arendrup MC, Fuursted K, Gahrn-Hansen B, Jensen IM, Knudsen JD, Lundgren B et al. Seminational surveillance of fungemia in Denmark: notably high rates of fungemia and numbers of isolates with reduced azole susceptibility. J Clin Microbiol. 2005;43:4434-4440.
5. Current WL, Tang J, Boylan C, Watson P, Zeckner W, Turner W. Glucan biosynthesis as a target for antifungal: the echinocandin class of antifungal agents. In: Dixon GK, Copping LG and Hollomon DW Editors. In Antifungal Agents: Discovery and Mode. BIOS, Oxford; 1995. pp. 143-160
6. Georgopapadakou NH and Walsh TJ. Antifungal agents: chemotherapeutic targets and immunologic strategies. Antimicrob Agents Chemother. 1996;40:270-91.
7. Maertens J, Vrebos M, Boogaerts M. Assessing risk factors for systemic fungal infections. Eur J Cancer Care. 2001;10(1):56-62.
8. Diamond RD. The growing problem of mycoses in patients infected with the human immunodeficiency virus. Rev Infect Dis. 1991;13:480-6.
9. Vazquez JA, Sanchez V, Dmuchowski C, Dembry LM, Sobel JD and Zervos MJ. Nosocomial acquisition of Candida albicans: an epidemiologic study. J Infect Dis. 1993;168:195-201.
10. Jantunen E, Ruutu P, Niskanen L, Volin L, Parkkali T, Koukila-Kahkola P et al. Incidence and risk factors for invasive fungal infections in allogeneic BMT recipients. Bone Marrow Transplantation. 1997;19:801-808
11. Ruping MJ, Vehreschild JJ, Cornely OA. Patients at high risk of invasive fungal infections: when and how to treat. Drugs. 2008;68(14):1941-62
12. Kriengkauykiat J, Ito JI, Dadwal SS. Epidemiology and treatment approaches in management of invasive fungal infections. Clin Epidemiol. 2011;3:175-91.
13. Staber P, Langner S, Dornbusch HJ, Neumeister P. Antifungal management in cancer patients. Wien Med Wochenschr. 2007;157(19-20):503-10.
14. Jorgensen KJ, Gotzsche PC, Johansen HK. Voriconazole versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev. 2006;25(1):CD004707.
15. Blyth CC, Hale K, Palasanthiran P, O'Brien T, Bennett MH. Antifungal therapy in infants and children with proven, probable or suspected invasive fungal infections. Cochrane Database Syst Rev. 2010;17(2):CD006343.
16. Clerihew L, Austin N, McGuire W. Prophylactic systemic antifungal agents to prevent mortality and morbidity in very low birth weight infants. Cochrane Database Syst Rev. 2007;17(4):CD003850.
17. Bolard J. How do the polyene macrolide antibiotics affect the cellular membrane properties? Biochemica et Biophysica Acta. 1986;864:257-304.
18. Warnock DW. Amphotericin B: an introduction. J Antimicrob Chemother. 1991;28(Suppl. B):27-38.
19. Kravetz HM, Andriole VT, Huber MA and Utz JP. Oral administration of solubilized amphotericin B. N Eng J Med. 1961;265:183-4
20. Bodey GP. Antifungal agents. In Bodey GP editor. Candidosis: Pathogenesis, Diagnosis and Treatment. Raven Press, New York;1993.p.371-406
21. Andriole VT and Bodey GP editors. Pocket Guide to Systemic Antifungal Therapy. Scientific Therapeutics, Springfield, NJ; 1994.
22. Bennett JE. Developing drugs for the deep mycoses: A short history. In: Bennett JE, Hay RJ and Peterson PK editors. New Strategies in Fungal Disease Churchill Livingstone, London; 1992. p. 3-12.
23. Bodey GP. Antifungal agents. In: Andriole VT editor. Current ID Drugs, Current Medicine, Philadelphia, PA; 1996. p. 229-48.
24. Plempel M, Bartmann K, Buchel KH and Regel E. First clinical experience in systemic mycoses with a new oral broad spectrum antimycotic. Deutsche Medizinische Wochenschrift.1969;94:1356.
25. Andriole VT. Current and future therapy of invasive fungal infections. In: Remington J and Swartz M editors. Current Clinical Topics in Infectious Diseases. Vol. 18. Blackwell Sciences, Malden, MA; 1998. p. 19-36.
26. Rex H, Bennett JE, Sugar AM, Pappas PG, vander Horst CM, Edwards JG et al. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Eng J Med. 1994;331:1325-30.
27. Anaissie EJ, Darouiche RO, Abi-Said D, Uzun O, Mera J, Gentry LO et al. Management of invasive candidal infections: results of a prospective randomized, multicenter study of fluconazole versus amphotericin B and review of the literature. Clin Infect Dis. 1996;23:964-72.
28. Kauffman CA. Role of azoles in antifungal therapy. Clin Infect Dis. 1996;22(Suppl 2):148-53.
29. Czwerwiec FS, Bilsker MS, Kamerman ML and Bisno AL. Long-term survival after fluconazole therapy of candidal prosthetic valve endocarditis. Am J Med. 1993;94;545-6.
30. Saag MS, Powderly WG, Cloud GA, Robinson P, Grieco MH, Sharkey PK et al. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cyrptococcal meningitis. N Eng J Med. 1992;326: 83-9.
31. Kauffman CA. Newer developments in therapy for endemic mycoses. Clin Infect Dis. 1994;19(Suppl 1):28-32.
32. Oakley KL, Moore CB and Denning DW. Comparison of in vitro activity of liposomal nystatin against Aspergillus species with those of nystatin, amphotericin B (AB) deoxycholate, AB colloidal dispersion, liposomal AB, AB lipid complex, and itraconazole. Antimicrob Agents Chemother. 1999;43:1264-1266.
33. Wallace TL, Paetznick V, Cossum PA, Anaissie E. Nyotran (liposomal nystatin) activity against disseminated Aspergillus fumigatus in neutropenic mice. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract B53, p. 9.
34. Gonzalez CE, Giri N, Shetty D, Kligys K, Love W, Sein T et al. Efficacy of a lipid formulation of nystatin against invasive pulmonary aspergillosis. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract B54, p. 31.
35. Desai S, Dokeb A, Disouzaa J, Athawale R. Development and evaluation of antifungal topical niosomal gel formulation. Int J Pharm Pharm Sci. 2011;3(suppl 5):224-231
36. Moen MD, Lyseng-Williamson KA, Scott LJ. Liposomal amphotericin B: a review of its use as empirical therapy in febrile neutropenia and in the treatment of invasive fungal infections. Drugs.2009;69(3):361-92.
37. Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother. 2002;49(suppl 1):81-86.
38. Guo LSS, Fielding RM and Lasic DD. Novel antifungal drug delivery: stable amphotericin B cholesteryl sulfate discs. Int J Pharm. 1991;75:45-54.
39. Amantea MA, Bowden RA, Forrest A, Working PK, Newman MS and Mamelok RD. Population pharmacokinetics and renal function-sparing effects of amphotericin B colloidal dispersion in patients receiving bone marrow transplants. Antimicrob Agents Chemother. 1995;39:2042-2047.
40. Fielding RM, Smith PC, Wang LH, Porter J and Guo LS. Comparative pharmacokinetics of amphotericin B after administration of a novel colloidal delivery system, ABCD, and a conventional formulation to rats. Antimicrob Agents Chemother. 1991;35:1208-1213.
41. Kondi V, Kamalinder S, Varma M, Alluri R, Karumuri SK. Formulation and evaluation of submicronic emulsions of amphotericin B. Int J Pharm Pharm Sci. 2012;4(suppl 1):153-159
42. George D, Miniter P and Andriole VT. Efficacy of UK-109496, a new azole antifungal agent, in an experimental model of invasive aspergillosis. Antimicrob Agents Chemother. 1996;40:86-91.
43. Troke PF, Brammer KW, Hitchcock CA, Yonren S and Sarantis N. UK-109496, a novel, wide-spectrum triazole derivative for the treatment of fungal infections: activity in systemic candidosis models and early clinical efficacy in oro-pharyngeal candidosis (OPC). In Program and Abstracts of the Thirty-Fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 1995. Abstract F73, p. 125.
44. Weiler S, Fiegl D, MacFarland R, Stienecke E, Bellmann-Weiler R, Dunzendorfer S et al. Human tissue distribution of voriconazole. Antimicrob Agents Chemother. 2011;55(2):925-8.
45. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4):225-34.
46. Zoller E, Valente C, Baker K, Klepser ME. Development, clinical utility, and place in therapy of posaconazole for prevention and treatment of invasive fungal infections. Drug Des Devel Ther. 2010;4:299-311
47. Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther. 2007;29(9):1862-86
48. Rachwalski EJ, Wieczorkiewicz JT, Scheetz MH. Posaconazole: an oral triazole with an extended spectrum of activity. Ann Pharmacother. 2008;42(10):1429-38.
49. Mehta AK, Langston AA. Use of posaconazole in the treatment of invasive fungal infections. Expert Rev Hematol. 2009;2(6):619-30.
50. Smith WJ, Drew RH, Perfect JR. Posaconazole's impact on prophylaxis and treatment of invasive fungal infections: an update. Expert Rev Anti Infect Ther. 2009;7(2):165-8
51. Fera MT, LaCamera E, De Sarro A. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance. Expert Rev Anti Infect Ther. 2009;7(8):981-98.
52. Pasqualotto AC, Thiele KO, Goldani LZ. Novel triazole antifungal drugs: focus on isavuconazole, ravuconazole and albaconazole. Curr Opin Investig Drugs. 2010;11(2):165-74.
53. Thompson GR 3rd, Wiederhold NP. Isavuconazole: a comprehensive review of spectrum of activity of a new triazole. Mycopathologia. 2010;170(5):291-313.
54. Ghannoum M, Isham N. Antifungal activity of BAL4815, a novel azole against dermatophytes and emerging nondermatophyte fungi Zygomycetes. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: 2005: abstract M-1623.
55. Warn P, Sharp A, Denning D. In vitro activity of BAL4815 against Zygomycetes. In: Proceedings of the 16th congress of the International Society for Human and Animal Mycology, France, 2006: abstract P-0158.
56. Guinea J, Bouza E. Isavuconazole: a new and promising antifungal triazole for the treatment of invasive fungal infections. Future Microbiol. 2008;3(6):603-15.
57. Dorsthorst D, Verweij P, Meis J, Mouton J. Pharmacodynamics of BAL4815: a new azole antifungal in a mouse model of systemic infection [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract A-1874.
58. Fung-Tomc JC, Huczko E, Minassian B, Bonner DP. In vitro activity of a new orial triazole, BMS-207147 (ER-30346). Antimicrob Agents Chemother. 1998;42:313-318.
59. Viljoen J, Mitha I, Heep M, Ghannoum M. Efficacy, safety, and tolerability of three different dosing regimens of BAL8557 vs. fluconazole in a double-blind, randomized, multicenter trial for the treatment of esophageal candidiasis in immunocompromised adults. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract LB2-32.
60. Schmitt-Hoffmann A, Roos B, Maares J, et al. Multiple-dose pharmacokinetics and safety of the new antifungal triazole BAL4815 after intravenous infusion and oral administration of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50:286-93.
61. Yan JH, Marino MR, Smith RA, Kanamaluru V, O'Mara EM, Grasela DM. The effect of ravuconazole on the pharmacokinetics of nelfinavir in healthy male volunteers. J Clin Pharmacol. 2006;46:193-200.
62. Cuenca-Estrella M, Gomez-Lopez A, Mellado E, Garcia-Effron G, Monzon A, Rodriguez-Tudela JL. In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi. Antimicrob Agents Chemother. 2005;49:5136-8.
63. Gupta AK, Leonardi C, Stoltz RR, Pierce PF, Conetta B. A phase I/II randomized, double-blind, placebo-controlled, dose-ranging study evaluating the efficacy, safety and pharmacokinetics of ravuconazole in the treatment of onychomycosis. J Eur Acad Dermatol Venereol. 2005;19: 437-43.
64. Albaconazole for fungal infections, Palaupharma. http://www.palaupharma.com/eng/pipeline_project.php?project=8. Assessed November 17, 2011
65. Project Factsheet, Palaupharma. http://www.palaupharma.com/media/uploads/pipeline/8/Factsheet%20Albaconazole%20Autumn%202011.pdf. Assessed November 17, 2011
66. Marcos da MG, Julio AU, Marta de L, Luis CCA, Vanja MV, Washington LT et al. Activity of the New Triazole Derivative Albaconazole against Trypanosoma cruzi in Dog Hosts. Antimicrob Agents Chemother. 2004;48(11):4286-4292
67. Miller L, Schell WA, Wills EA, Toffaletti DL, Boyce M, Benjamin DK et al. In Vitro and In Vivo Efficacies of the new triazole Albaconazole against Cryptococcus neoformans. J Antimicrob Agents Chemother. 2004;48(2):384-387.
68. Sucher AJ, Chahine EB, Balcer HE. Echinocandins: the newest class of antifungals. Ann Pharmacother. 2009;43(10):1647-57.
69. David WD. Echinocandins: a new class of antifungal. J Antimicrob Chemother. 2002;49(6):889-891
70. Pfaller MA, Boyken L, Hollis RJ, Kroeger J, Messer SA, Tendolkar S et al. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J Clin Microbiol. 2008;46(1):150-6.
71. Espinel-Ingroff A. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature. Rev Iberoam Micol. 2003;20(4):121-36.
72. Johnson MD, Perfect JR. Caspofungin: first approved agent in a new class of antifungals. Expert Opin Pharmacother. 2003;4(5):807-23.
73. Agarwal MB, Rathi SA, Ratho N, Subramanian R. Caspofungin: a major breakthrough in treatment of systemic fungal infections. J Assoc Physicians India. 2006;54:943-8.
74. Keating G, Figgitt D. Caspofungin: a review of its use in oesophageal candidiasis, invasive candidiasis and invasive aspergillosis. Drugs. 2003;63(20):2235-63.
75. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391-402.
76. Mattiuzzi GN, Alvarado G, Giles FJ, Ostrosky-Zeichner L, Cortes J, O'Brien S et al. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob Agents Chemother. 2006;50(1):143-7.
77. Villanueva A, Gotuzzo E, Arathoon EG, Noriega LM, Kartsonis NA, Lupinacci RJ et al. A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am J Med. 2002;113(4):294-9.
78. Arathoon EG, Gotuzzo E, Noriega LM, Berman RS, DiNubile MJ, Sable CA. Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob Agents Chemother. 2002;46(2):451-7.
79. Zaoutis TE, Jafri HS, Huang LM, Locatelli F, Barzilai A, Ebell W et al. A prospective, multicenter study of caspofungin for the treatment of documented Candida or Aspergillus infections in pediatric patients. Pediatrics. 2009;123(3):877-84.
80. Winkler M, Pratschke J, Schulz U, Zheng S, Zhang M, Li W, Lu M et al. Caspofungin for post solid organ transplant invasive fungal disease: results of a retrospective observational study. Transpl Infect Dis. 2010;12(3):230-7.
81. Petrovic J, Ngai A, Bradshaw S, Williams-Diaz A, Taylor A, Sable C et al. Efficacy and safety of caspofungin in solid organ transplant recipients. Transplant Proc. 2007;39(10):3117-20.
82. Cornely OA, Lasso M, Betts R, Klimko N, Vazquez J, Dobb G et al. Caspofungin for the treatment of less common forms of invasive candidiasis. J Antimicrob Chemother. 2007;60(2):363-9.
83. Pettengell K, Mynhardt J, Kluyts T, Lau W, Facklam D, Buell D. Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent. Aliment Pharmacol Ther. 2004;20(4):475-81.
84. De Wet NT, Bester AJ, Viljoen JJ, Filho F, Suleiman JM, Ticona E et al. A randomized, double blind, comparative trial of micafungin (FK463) vs. fluconazole for the treatment of oesophageal candidiasis. Aliment Pharmacol Ther. 2005;21(7):899-907.
85. Pappas PG, Rotstein CM, Betts RF, Nucci M, Talwar D, De Waele JJ et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis. 2007;45(7):883-93.
86. Van Burik JA, Ratanatharathorn V, Stepan DE, Miller CB, Lipton JH, Vesole DH et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. J Clin Infect Dis. 2004;39(10):1407-16.
87. Sohn HS, Lee TJ, Kim J, Kim D. Cost-effectiveness analysis of micafungin versus fluconazole for prophylaxis of invasive fungal infections in patients undergoing hematopoietic stem cell transplantation in Korea. Clin Ther. 2009;31(5):1105-15.
88. Wilke M. Treatment and prophylaxis of invasive candidiasis with anidulafungin, caspofungin and micafungin and its impact on use and costs: review of the literature. Eur J Med Res. 2011;16(4):180-6.
89. Sidhu MK, van Engen AK, Kleintjens J, Schoeman O, Palazzo M. Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida infections in the UK. Curr Med Res Opin. 2009 Aug;25(8):2049-59.
90. Flynn PM, Seibel N, Arrieta A, et al. Treatment of invasive aspergillosis (ia) in pediatric patients with micafungin alone or in combination with other systemic antifungal agents. Abstracts of the 46th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2006; San Francisco, CA: American Society for Microbiology. 2006. p. 407.
91. De WN, Llanos-Cuentas A, Suleiman J, Baraldi E, Krantz EF et al. A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients. Clin Infect Dis. 2004;39(6):842-9.
92. Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole. J Clin Microbiol. 2005;43(11):5425-7.
93. Krause DS, Simjee AE, van Rensburg C, Viljoen J, Walsh TJ, Goldstein BP. A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis. Clin Infect Dis. 2004;39(6):770-5.
94. Reboli AC, Rotstein C, Pappas PG, Chapman SW, Kett DH, Kumar D et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med. 2007; 356(24):2472-82.
95. Krause DS, Reinhardt J, Vazquez JA, Reboli A, Goldstein BP, Wible M, Henkel T. Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia. Antimicrob Agents Chemother. 2004;48(6):2021-4.
96. Pfaller MA, Diekema DJ, Boyken L, Messer SA, Tendolkar S, Hollis RJ, Goldstein BP. Effectiveness of anidulafungin in eradicating Candida species in invasive candidiasis. Antimicrob Agents Chemother. 2005;49(11):4795-7.
97. Dominguez JM, Martin JJ. Identification of elongation factor 2 as the essential protein targeted by sordarins in Candida albicans. Antimicrob Agents Chemother. 1998;42(9):2279-83.
98. Dominguez JM, Kelly VA, Kinsman OS, Marriott MS, Gomez de las Heras F, Martin J. Sordarins: a new class of antifungals with selective inhibition of the protein synthesis elongation cycle in yeasts. Antimicrob Agents Chemother. 1998;42(9): 2274-8.
99. Lozano-Chiu M, Paetznick VL, Rodriguez JR, Rex JH. Anti-Candida activity of the sordarin derivatives GW471552, GW47558, GW506540, GW531920 and GW560849: effect of endpoint role and incubation time on MIC. Presented at the interscience conference on antimicrobial agents and chemotherapy, Toronto, Ontario Canada, September 17-20, 2000.
100. Martinez A, Aviles P, Jimenez E, Caballero J, Gargallo-Viola D. Activities of sordarins in experimental models of candidiasis, aspergillosis, and pneumocystosis. Antimicrob Agents Chemother. 2000;44(12):3389-94.
101. Goldberg J, Connolly P, SchnizleIn-Bick C, et al. Comparison of nikkomycin Z with amphotericin B and itraconazole for treatment of histoplasmosis in a murine model. Antimicrob Agents Chemother. 2000;44(6):1624-9.
102. Clemons KV, Stevens DA. Efficacy of nikkomycin Z against experimental pulmonary blastomycosis. Antimicrob Agents Chemother 1997;41(9):2026-8.
103. Hector RF, Zimmer GL, Pappagianis D. Evaluation of nikkomycins X and Z in murine models of coccidioidomycosis, histoplasmosis, and blastomycosis. Antimicrob Agents Chemother. 1990;34(4):587-93.
104. Debono M, Gordee RS. Antibiotics that inhibit fungal cell wall development. Annu Rev Microbiol. 1994;48:471-97.
105. Li RK, Fothergill AW and Rinaldi MG. In vitro antifungal activity of SP-920704 in combination with fluconazole and itraconazole. In Program and Abstracts of the Thirty-Sixth Interscience Conference on Antimicrobial Agents and Chemotherapy, New Orleans, LA, 1996. Abstract F189, p. 132.
106. Graybill JR, Najvar LK, Bocanegra R, Hector RF and Luther MF. Efficacy of nikkomycin Z in the treatment of murine histoplasmosis. Antimicrob Agents Chemother. 1998;42:2371-4.
107. Pachl J, Svoboda P, Jacobs F. A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis. 2006;42:1404-13.
108. Hodgetts S, Nooney L, Awad S, Matthews R. Mycograb in combination with caspofungin in murine models of candidiasis. In: Program and abstracts of the 46th interscience conference on antimicrobial agents and chemotherapy, Washington, DC: American Society for Microbiology, 2006: abstract M-1751.
109. Marcio L. Rodrigues, Li Shi, Eliana B, Leonardo N, Sandra E et al. Monoclonal Antibody to Fungal Glucosylceramide Protects Mice against Lethal Cryptococcus neoformans Infection. Clin Vaccine Immunol. 2007;14(10):1372-1376.
110. Kondori N, Edebo L, Mattsby-Baltzer I. A novel monoclonal antibody recognizing beta(1-3) glucans in intact cells of Candida and Cryptococcus. APMIS 2008;116(10):867-76.
111. Najvar L, Bocanegra R, Olivo M, Molina D. Once is enough: single dose aminocandin therapy of candidemia. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract F-496.
112. Warn P, Sharp A, Denning D. Dose response curves and dose fractionation studies with aminocandin in a murine model of disseminated aspergillosis. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract F-495.
113. Peter AW, Andrew S, Graham Morrissey and David WD. Activity of aminocandin (IP960) compared with amphotericin B and fluconazole in a neutropenic murine model of disseminated infection caused by a fluconazole-resistant strain of Candida tropicalis. J Antimicrob Chemother. 2005;56(3):590-593.
114. Brzankalski G, Bocanegra R, Najvar L, Olivo M. Efficacy of aminocandin in treatment of Candida glabrata in mice. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: abstract F-1624.
115. Gabriela EB, Laura KN, Nathan PW, Rosie B, Annette WF, Michael GR et al. Evaluation of aminocandin and caspofungin against Candida glabrata including isolates with reduced caspofungin susceptibility. J Antimicrob Chemother. 2008;62(5):1094-1100.
116. Warn P, Sharp A, Denning D. Activity of aminocandin (IP960; HMR3270) compared with amphotericin B, itraconazole, caspofungin and micafungin in neutropenic murine models of disseminated infection caused by itraconazole-susceptible and resistant strains of Aspergillus fumigates. Int J Antimicrob Agents.2010;35(2)146-151.
117. Najvar LK, Bocanegra R, Wiederhold NP, Lambros C, Najarian N, Patterson TF et al. Therapeutic and prophylactic efficacy of aminocandin (IP960) against disseminated candidiasis in mice. Clin Microb Infect. 2008; 14(6): 595-600
118. Brummer E, Morrison CJ, Stevens DA. Recombinant and natural g-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immunol. 1985;49:724-30.
119. Brummer E, Stevens DA. Candidacidal mechanisms of peritoneal macrophages activated with lymphokines or g-interferon. J Med Microbiol. 1989;28:173-81.
120. Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferon-γ in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis. 1994;170:1331-4.